Apogee Reports Positive Interim Results for APG777 in Asthma Trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Should l Buy APGE?
Source: Globenewswire
- Clinical Trial Progress: APG777 demonstrated significant FeNO suppression in asthma patients, with a maximum absolute mean reduction of 45 ppb (60% decrease from baseline) after a single 720 mg dose, indicating the drug's potential in treating Type 2 inflammation and providing new therapeutic options for the future market.
- Long-term Efficacy Validation: FeNO suppression was observed in all patients through 16 weeks, with some maintaining suppression through 32 weeks, supporting the potential for 3- or 6-month dosing, which could transform treatment paradigms for asthma patients.
- Financial Backing: As of September 2025, Apogee holds $913 million in cash reserves, expected to support the advancement of APG777 towards a potential launch in 2029, ensuring the company's sustained growth in the competitive biopharmaceutical market.
- Future Milestones: The company anticipates releasing 52-week maintenance data for APG777 in atopic dermatitis in 2026, further solidifying its best-in-class potential in a market exceeding $50 billion, driving strategic positioning in the immunology and inflammation sectors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APGE
Wall Street analysts forecast APGE stock price to rise
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 69.310
Low
83.00
Averages
105.67
High
137.00
Current: 69.310
Low
83.00
Averages
105.67
High
137.00
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Atopic Dermatitis Market Growth Insights
- Market Size Growth: The atopic dermatitis treatment market is expected to continue growing positively by 2034, with the United States holding the largest market share, reflecting strong demand for new therapies that drive overall market expansion.
- Introduction of New Therapies: The launch of new therapies such as Rocatinlimab and Amlitelimab is anticipated to transform the market landscape by providing more effective treatment options to meet the increasing patient demand.
- Rising Patient Numbers: In 2024, approximately 53 million diagnosed cases of atopic dermatitis are expected in the 7MM, with the increase in patient numbers directly fueling the demand for advanced treatment options and promoting market growth.
- Changing Competitive Landscape: As new drugs undergo clinical trials and enter the market, competition will intensify, particularly with companies like Eli Lilly leveraging their product portfolios to capture significant market share in the EU4 and Japan, showcasing strong market potential.
See More
Affinity Asset Advisors Increases Stake in Apogee Therapeutics
- Increased Holdings: Affinity Asset Advisors disclosed a purchase of 61,500 shares of Apogee Therapeutics during Q4 2025, with an estimated trade value of $3.87 million, indicating strong confidence in the company.
- Value Appreciation: Following this acquisition, Affinity's total stake in Apogee reached 1,234,926 shares, with a value increase of $46.59 million, reflecting an impressive 86.9% rise in the company's stock price over the past year.
- Portfolio Concentration: Apogee now constitutes 6.9% of Affinity's total assets under management, ranking as the top holding among its five largest positions, showcasing significant trust in its monoclonal antibody pipeline.
- Outstanding Market Performance: Apogee's stock delivered an alpha of 75.14 percentage points over the S&P 500, underscoring its robust performance in the biotechnology sector and potential for future growth.
See More
Apogee Therapeutics (APGE.US) Officer Plans to Sell $3.84 Million in Common Stock via Form 144
Stock Sale Announcement: Henderson Michael Thomas plans to sell 60,000 shares of Apogee Therapeutics common stock on February 11, with an estimated market value of approximately $3.84 million.
Reduction in Shareholding: Thomas has reduced his shareholding in Apogee Therapeutics by 80,000 shares since December 4, 2025, with a total value of around $6.13 million.
See More
Apogee Therapeutics (APGE) Options Volume Surges 46.6% Today
- Active Options Trading: Apogee Therapeutics has seen an options volume of 4,166 contracts today, equating to approximately 416,600 shares, indicating a trading activity level of 46.6% of its average daily volume over the past month.
- High Demand Options: Notably, the $90 strike call option expiring on March 20, 2026, has seen a significant volume of 2,505 contracts traded today, representing about 250,500 shares, reflecting strong market interest at this strike price.
- Ceva Inc Options Activity: Concurrently, Ceva Inc has recorded an options volume of 1,294 contracts today, approximately 129,400 shares, which corresponds to 45.8% of its average daily trading volume over the past month.
- Increased Interest in Strike Price: Among Ceva's options, the $30 strike call option expiring on February 20, 2026, has seen a trading volume of 506 contracts today, representing around 50,600 shares, indicating a rising market focus on this strike price.
See More
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Stock Picks Overview: The second installment of the 2026 Barron’s Roundtable features 30 stock picks from five investment experts, highlighting both well-known companies and lesser-known options.
Familiar Names Included: Among the stock picks are recognizable brands such as Home Depot, Starbucks, and Nike, indicating a mix of established and emerging investment opportunities.
Biodegradable Innovation: The article hints at a British company that has recently acquired a manufacturer of biodegradable sneaker midsoles, showcasing a trend towards sustainable products in the footwear industry.
Investment Insights: The Roundtable serves as a platform for sharing diverse investment strategies and insights, appealing to both seasoned investors and those looking to explore new market trends.
See More
Apogee Therapeutics CMO Sells $1.46 Million in Shares
- Share Sale: Carl Dambkowski, CMO of Apogee Therapeutics, sold 18,700 shares for approximately $1.46 million, reducing his direct holdings by 8.09% from 231,223 to 212,523 shares, indicating a structured liquidity management approach.
- Option Exercise: Prior to the sale, Dambkowski exercised 14,025 stock options, maintaining a substantial stake worth about $16.8 million, which reflects his ongoing confidence in the company's future prospects.
- Market Performance: Apogee Therapeutics shares have surged approximately 60% over the past year, significantly outperforming the S&P 500's 18% gain, indicating growing market confidence in its immunology pipeline and competitive positioning in the biotech sector.
- Financial Position: As of the third quarter, Apogee reported $913 million in cash and cash equivalents, ensuring funding through the second half of 2028, which supports its strategic development in clinical-stage biologics.
See More
Atopic Dermatitis Market Growth Insights
- Market Size Growth: The atopic dermatitis treatment market is expected to continue growing positively by 2034, with the United States holding the largest market share, reflecting strong demand for new therapies that drive overall market expansion.
- Introduction of New Therapies: The launch of new therapies such as Rocatinlimab and Amlitelimab is anticipated to transform the market landscape by providing more effective treatment options to meet the increasing patient demand.
- Rising Patient Numbers: In 2024, approximately 53 million diagnosed cases of atopic dermatitis are expected in the 7MM, with the increase in patient numbers directly fueling the demand for advanced treatment options and promoting market growth.
- Changing Competitive Landscape: As new drugs undergo clinical trials and enter the market, competition will intensify, particularly with companies like Eli Lilly leveraging their product portfolios to capture significant market share in the EU4 and Japan, showcasing strong market potential.
See More
Affinity Asset Advisors Increases Stake in Apogee Therapeutics
- Increased Holdings: Affinity Asset Advisors disclosed a purchase of 61,500 shares of Apogee Therapeutics during Q4 2025, with an estimated trade value of $3.87 million, indicating strong confidence in the company.
- Value Appreciation: Following this acquisition, Affinity's total stake in Apogee reached 1,234,926 shares, with a value increase of $46.59 million, reflecting an impressive 86.9% rise in the company's stock price over the past year.
- Portfolio Concentration: Apogee now constitutes 6.9% of Affinity's total assets under management, ranking as the top holding among its five largest positions, showcasing significant trust in its monoclonal antibody pipeline.
- Outstanding Market Performance: Apogee's stock delivered an alpha of 75.14 percentage points over the S&P 500, underscoring its robust performance in the biotechnology sector and potential for future growth.
See More
Apogee Therapeutics (APGE.US) Officer Plans to Sell $3.84 Million in Common Stock via Form 144
Stock Sale Announcement: Henderson Michael Thomas plans to sell 60,000 shares of Apogee Therapeutics common stock on February 11, with an estimated market value of approximately $3.84 million.
Reduction in Shareholding: Thomas has reduced his shareholding in Apogee Therapeutics by 80,000 shares since December 4, 2025, with a total value of around $6.13 million.
See More
Apogee Therapeutics (APGE) Options Volume Surges 46.6% Today
- Active Options Trading: Apogee Therapeutics has seen an options volume of 4,166 contracts today, equating to approximately 416,600 shares, indicating a trading activity level of 46.6% of its average daily volume over the past month.
- High Demand Options: Notably, the $90 strike call option expiring on March 20, 2026, has seen a significant volume of 2,505 contracts traded today, representing about 250,500 shares, reflecting strong market interest at this strike price.
- Ceva Inc Options Activity: Concurrently, Ceva Inc has recorded an options volume of 1,294 contracts today, approximately 129,400 shares, which corresponds to 45.8% of its average daily trading volume over the past month.
- Increased Interest in Strike Price: Among Ceva's options, the $30 strike call option expiring on February 20, 2026, has seen a trading volume of 506 contracts today, representing around 50,600 shares, indicating a rising market focus on this strike price.
See More
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Stock Picks Overview: The second installment of the 2026 Barron’s Roundtable features 30 stock picks from five investment experts, highlighting both well-known companies and lesser-known options.
Familiar Names Included: Among the stock picks are recognizable brands such as Home Depot, Starbucks, and Nike, indicating a mix of established and emerging investment opportunities.
Biodegradable Innovation: The article hints at a British company that has recently acquired a manufacturer of biodegradable sneaker midsoles, showcasing a trend towards sustainable products in the footwear industry.
Investment Insights: The Roundtable serves as a platform for sharing diverse investment strategies and insights, appealing to both seasoned investors and those looking to explore new market trends.
See More
Apogee Therapeutics CMO Sells $1.46 Million in Shares
- Share Sale: Carl Dambkowski, CMO of Apogee Therapeutics, sold 18,700 shares for approximately $1.46 million, reducing his direct holdings by 8.09% from 231,223 to 212,523 shares, indicating a structured liquidity management approach.
- Option Exercise: Prior to the sale, Dambkowski exercised 14,025 stock options, maintaining a substantial stake worth about $16.8 million, which reflects his ongoing confidence in the company's future prospects.
- Market Performance: Apogee Therapeutics shares have surged approximately 60% over the past year, significantly outperforming the S&P 500's 18% gain, indicating growing market confidence in its immunology pipeline and competitive positioning in the biotech sector.
- Financial Position: As of the third quarter, Apogee reported $913 million in cash and cash equivalents, ensuring funding through the second half of 2028, which supports its strategic development in clinical-stage biologics.
See More
